BIO 024Alternative Names: BIO024
Latest Information Update: 26 Aug 2015
At a glance
- Originator Gardant Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alopecia
Most Recent Events
- 04 Jan 2007 Gardant Pharmaceuticals has been acquired by Switch Pharma
- 22 Oct 2005 Phase-II clinical trials in Alopecia in USA (Topical)